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Population differences in death rates in HIV-positive patients 
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SETTING: Randomised controlled clinical trial of My-
cobacterium vaccae vaccination as an adjunct to anti-
tuberculosis treatment in human immunodeficiency virus
(HIV) positive patients with smear-positive tuberculosis
(TB) in Lusaka, Zambia, and Karonga, Malawi.
OBJECTIVE: To explain the difference in mortality be-
tween the two trial sites and to identify risk factors for
death among HIV-positive patients with TB.
DESIGN: Information on demographic, clinical, labora-
tory and radiographic characteristics was collected. Pa-
tients in Lusaka (667) and in Karonga (84) were followed
up for an average of 1.56 years. Cox proportional hazard
analyses were used to assess differences in survival between
the two sites and to determine risk factors associated with
mortality during and after anti-tuberculosis treatment.
RESULTS: The case fatality rate was 14.7% in Lusaka
and 21.4% in Karonga. The hazard ratio for death com-
paring Karonga to Lusaka was 1.47 (95% confidence in-
terval [CI] 0.9–2.4) during treatment and 1.76 (95%CI
1.0–3.0) after treatment. This difference could be almost
entirely explained by age and more advanced HIV dis-
ease among patients in Karonga.
CONCLUSION: It is important to understand the reasons
for population differences in mortality among patients
with TB and HIV and to maximise efforts to reduce
mortality.
KEY WORDS: tuberculosis; HIV; mortality; sub-Saharan
Africa
MORTALITY in human immunodeficiency virus
(HIV) infected patients with tuberculosis (TB) is high
in the absence of antiretroviral treatment (ART). Many
of these deaths are probably from causes not related
to TB.1 Case-fatality rates (CFR) recorded in this group
vary greatly, ranging from less than 10% to more than
40%, in studies from sub-Saharan Africa.2–14
These differences may be explained to some extent
by the stage and severity of the HIV epidemic: as the
epidemic matures, the proportion of TB patients who
are HIV-infected, the average duration of HIV infection,
the degree of immunosuppression among these pa-
tients, and the burden on the health services all in-
crease. This is illustrated in Figure 1, which shows a
strong correlation between HIV prevalence in TB pa-
tients and the CFR of those with HIV co-infection
(r2 0.38, P  0.02). Whether there are other reasons
for the differences observed between populations is
unclear.
In-depth comparisons of outcomes between sites
are difficult: treatments, duration of treatment, losses
to follow-up and patient mix all vary. Using data from
a trial of Mycobacterium vaccae vaccination15 which
had been proposed as an adjunct to TB therapy, we
had the opportunity to explore outcomes in Lusaka,
Zambia, and Karonga District, Malawi. M. vaccae
had no effect on survival or treatment outcome, but it
was noted that survival rates were much lower in
Karonga than in Lusaka (Figure 2). As the data were
collected in the same way in both sites, a detailed
comparison was possible.
METHODS
The original study was a two-centre randomised,
double-blind, placebo-controlled clinical trial of M. vac-
cae immunotherapy in adult patients with smear-
positive TB co-infected with HIV.15 Patients with newly
diagnosed previously untreated smear-positive pulmo-
nary TB were recruited between September 1996 and
October 1998 at the two trial sites: the University
Teaching Hospital in Lusaka, Zambia, and the Ka-
ronga Prevention Study in Karonga, a rural district of
northern Malawi. Patients were randomly allocated
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to receive either a single dose of killed M. vaccae or
placebo within the first 14 days of initiating anti-
tuberculosis treatment.
Patients received standard short-course anti-
tuberculosis treatment according to the current coun-
try guidelines. Antiretrovirals, cotrimoxazole or iso-
niazid (INH, H) prophylaxis were not available at the
time at either site. Patients in Lusaka received 2 months
of INH, rifampicin (RMP, R), pyrazinamide (PZA, Z)
and ethambutol (EMB, E), followed by 6 months of HE
(2HRZE/6HE). Drugs were given on an out-patient
basis and self-administered throughout treatment. Pa-
tients in Karonga received HRZ and streptomycin
(SM, S) for 2 months in hospital, followed by 6 months
of HE as out-patients (2HRZS/6HE).
At baseline, the history and presence of HIV-related
signs and symptoms were recorded, weight and height
were measured, blood samples were taken for HIV se-
rology and haemoglobin levels, chest radiography was
performed and an additional sputum sample was taken
for sputum culture.
At each follow-up visit (every 4 weeks during treat-
ment and every 12 weeks thereafter), patients were
examined, signs and symptoms of HIV-related illnesses
were recorded and sputum samples were taken for
smear and culture. Chest X-rays (CXRs) were taken
at the end of treatment and at months 12 and 18.
CXRs were reviewed by an independent blinded
assessor as part of the multi-centre study to assess the
effect of M. vaccae immunotherapy on radiographic
healing in TB.16 For each radiograph, the assessor re-
corded the number of zones affected, aggregated ex-
tent of pulmonary disease, and presence of cavitation,
hilar/mediastinal adenopathy, miliary TB, pleural ef-
fusion and infiltration.
Statistical analysis
Patients were assigned a World Health Organization
(WHO) HIV clinical stage17 according to the signs
and symptoms recorded at the beginning and at the
end of anti-tuberculosis treatment (week 32/34). At
the beginning of treatment, the following signs and
symptoms were included in the categorisation: minor
mucocutaneous manifestations, history of herpes zoster
in last 5 years, unexplained chronic diarrhoea for more
than one month, oral candidiasis, herpes simplex virus
infection and Kaposi’s sarcoma. Signs and symptoms
typical of TB (prolonged fever, weight loss and wast-
ing syndrome) as well as current or previous TB were
excluded. The categorisation at the end of treatment
was done independently of the staging assigned at base-
line, using the same criteria but also including pro-
longed fever, weight loss and wasting syndrome.
The data were analysed using STATA™ 9.2 soft-
ware (Stata Corporation, College Station, TX, USA).
The CFR was calculated as the number of deaths dur-
ing anti-tuberculosis treatment divided by the number
of patients initiating treatment. Death rates were cal-
culated by dividing the number of deaths by the person-
years (py) of observation, calculated from the date of
beginning treatment until the end of follow-up or time
of death. Patients lost to follow-up were censored at
the time of their last visit.
Cox proportional hazard models were used to com-
pare mortality rates between the two sites. The propor-
tional hazards assumption was checked by visual in-
spection of Nelson-Aalen plots and by performing tests
for interaction with time. All analyses were performed
for the whole follow-up period and separately for the
time during and after anti-tuberculosis treatment.
We used univariate Cox regression to assess the ef-
fect of each risk factor on the death rate for each site
separately. With bivariate Cox regression we examined
the possible confounding effect of each risk factor on
the hazard ratio (HR) of death in Karonga compared
to Lusaka. We used multivariate Cox regression to
explain the difference between the two sites. In addi-
tion, we used data from both sites to determine risk
factors associated with mortality of HIV-positive pa-
tients during and after anti-tuberculosis treatment.
Figure 1 Case-fatality rates of patients with tuberculosis co-
infected with HIV, compared to HIV prevalence among tubercu-
losis patients in different settings in sub-Saharan Africa. Each
diamond represents a different study.1–13 HIV  human immuno-
deficiency virus.
Figure 2 Kaplan-Meier survival curve, comparing survival of
HIV-positive patients with smear-positive pulmonary tuberculosis
in Lusaka, Zambia (solid line) and Karonga, Malawi (dashed line).
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Ethical approval
This analysis was approved by the London School of
Hygiene & Tropical Medicine Ethics Committee. The
original study was approved by review boards at the
University Teaching Hospital, the University of Zam-
bia School of Medicine, the Health Sciences Research
Committee of the Ministry of Health, Malawi, and
the London School of Hygiene & Tropical Medicine.
RESULTS
Between September 1996 and October 1998, 1442
patients with pulmonary TB were screened, 1184 in
Lusaka and 258 in Karonga, and respectively 996 and
149 were randomised into the trial. The main reasons
for exclusion were lack of bacteriological confirma-
tion of TB (n  78), previous anti-tuberculosis treat-
ment (n  49), ineligible age or area of residence (n 
66), pregnancy (n  10) and not giving consent (n 
48). Four patients in Lusaka and 21 in Karonga were
deemed too ill. In Lusaka, 67% (667/996) were HIV-
positive, and in Karonga 56% (84/149). Patients were
followed up for an average of 1.56 years in Lusaka
and 1.59 years in Karonga; the maximum follow-up
time was 3.13 years.
Overall, 230 patients died; of these, 216 were
HIV-positive. In Lusaka, the CFR was 14.7% in HIV-
positive patients and 0.6% in HIV-negative patients,
and in Karonga, 21.4% in HIV-positive and 1.5% in
HIV-negative patients. Mortality rates are shown
in Table 1. The overall mortality rate among HIV-
positive patients was 18.2/100 py in Lusaka and 30.0/
100 py in Karonga. Increased mortality was observed
in Karonga both during and after treatment. The mor-
tality rates also differed among HIV-negative patients,
but the number of deaths was small and the confi-
dence interval wide. Further analysis is therefore re-
stricted to HIV-positive patients.
Table 1 Mortality rates and hazard ratios comparing Lusaka and Karonga throughout the follow-up period, during 
anti-tuberculosis treatment and after treatment
Lusaka Karonga
py
Deaths
n Rate (95%CI) py
Deaths
n Rate (95%CI) HR (95%CI) P value*
All patients
Overall 1559.7 192 12.3 (10.7–14.2) 236.5 38 16.1 (11.7–22.1) 1.29 (0.9–1.9) 0.15
During treatment 598.5 100 16.7 (13.7–20.3) 91.9 19 20.7 (13.2–32.4) 1.23 (0.7–2.0) 0.40
After treatment 961.3 92 9.6 (7.8–11.7) 144.6 19 13.1 (8.4–20.6) 1.36 (0.8–2.2) 0.22
HIV-positive
Overall 999.7 182 18.2 (15.7–21) 113.4 34 30.0 (21.4–42.0) 1.60 (1.1–2.3) 0.01
During treatment 394.5 98 24.8 (20.4–30.3) 49.0 18 36.7 (23.1–58.3) 1.47 (0.9–2.4) 0.13
After treatment 605.2 84 13.9 (11.2–17.2) 64.4 16 24.9 (15.2–40.6) 1.76 (1.0–3.0) 0.04
HIV-negative
Overall 560.0 10 1.8 (1–3.3) 123.1 4 3.2 (1.2–8.6) 1.82 (0.6–5.7) 0.31
During treatment 204.0 2 1.0 (0.2–3.9) 42.9 1 2.3 (0.3–16.6) 2.42 (0.2–26.7) 0.47
After treatment 356.0 8 2.2 (1.1–4.5) 80.2 3 3.7 (1.2–11.6) 1.67 (0.4–6.3) 0.45
* P value from Wald test.
py  person-years; HR  hazard ratio; CI  confidence interval; HIV  human immunodeficiency virus.
Patient characteristics
Table 2 shows the characteristics of the HIV-positive
patients. Compared to the patients in Lusaka, the pa-
tients in Karonga were older, a higher proportion had a
body mass index (BMI) in the lowest group (severely
malnourished) and a higher proportion had HIV-
related signs and symptoms, both at the beginning and
at the end of anti-tuberculosis treatment. Patients in
Karonga were less likely to have cavities on CXR and
more likely to have hilar/mediastinal lymphadenopathy.
Risk factors for mortality
The associations between patient characteristics and
mortality throughout the period of follow-up are shown
in Table 3. Mortality rates increased with age but were
similar in men and women. Low BMI, low level of
haemoglobin and more advanced clinical stage of HIV
at baseline were strong predictors of mortality. Clini-
cal stage at the end of anti-tuberculosis treatment was
strongly associated with subsequent mortality.
Patients with cavitation or a larger proportion of
lungs affected on the baseline CXR had lower mortal-
ity rates (Table 3). Patients at highest risk were those
with no radiological changes.
Comparing Lusaka and Karonga
In the bivariate proportional hazards analysis, the
overall HR of 1.60, comparing mortality at the two
sites (Table 1), was reduced by adjusting for age (ad-
justed HR [aHR] 1.40, 95% confidence interval [CI]
1.0–2.0) and clinical stage at the beginning of treat-
ment (aHR 1.47, 95%CI 1.0–2.1), but was not changed
by adjusting for any other demographic or clinical
factor. Among those with CXRs available, the overall
HR comparing the sites was 1.74 (95%CI 1.2–2.6).
The only radiological feature that explained some of
the difference between sites was absence of cavitation
(aHR 1.56, 95%CI 1.0–2.3). Age, baseline HIV stage
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and absence of cavitation on CXR were the main
factors explaining the increased mortality rate in
Karonga, both during and after treatment. The larg-
est single risk factor explaining the difference in mor-
tality after the end of treatment was HIV stage at
week 32 (reducing the HR from 1.76 to 1.20, 95%CI
0.6–2.2).
The overall HR for death in Karonga compared to
Lusaka was reduced to 1.22 (95%CI 0.8–1.8) after
adjusting in the multivariate model for age, HIV stage
at baseline and absence of cavitation on CXR. The
HR for death during treatment fell from 1.64 (in
those with CXR available) to 1.19 (95%CI 0.6–2.2)
adjusting for the same factors. For death after treat-
ment the HR fell from 1.76 to 0.81 (95%CI 0.4–1.6)
after adjusting for age, HIV stage at baseline and HIV
stage at the end of treatment.
Multivariate analysis of risk factors for mortality
The risk factors that were found to be significantly as-
sociated with mortality in multivariate analyses are
shown in Table 4. Study site was retained in the model
a priori.
Age was a strong risk factor for mortality during
both time periods. Low BMI, low level of haemoglo-
bin and absence of cavitation on CXR were strong
risk factors for death during anti-tuberculosis treat-
ment. HIV stage at the beginning of treatment was no
longer a significant risk factor once adjusted for other
variables. After treatment, HIV stage and haemoglo-
bin levels at baseline and HIV stage at the end of treat-
ment were important risk factors for mortality.
DISCUSSION
The difference in mortality between Karonga and Lu-
saka appears to be attributable largely to differences
in age (patients in Karonga were older) and stage of
HIV infection: patients in Karonga had more advanced
HIV disease both at the beginning and at the end of
anti-tuberculosis treatment, and were less likely to
have cavitation on CXR.
Age and stage of HIV disease have been identified
as risk factors for death in HIV-positive TB patients in
previous studies.3,6,14,18,19 Clinical stage is difficult to
assess in patients with active TB. We excluded those
signs and symptoms that overlapped with signs and
symptoms of TB to be able to detect differences in
HIV disease (if not, the majority of patients would
fall in WHO stage 3) but misclassification is likely. In
the multivariate analysis, other risk factors (BMI, hae-
moglobin and absence of cavitation on CXR) were
better predictors of mortality during treatment, prob-
ably because they were better correlates of immune
deficiency. Low BMI has been identified as an inde-
pendent risk factor for mortality in HIV-positive pa-
tients20 and an important predictor of early death of
patients on anti-tuberculosis treatment in an area with
high HIV prevalence.21 Anaemia has been previously
identified as a risk factor for HIV-associated mortal-
ity,22 independently of viral load or CD4 count.23
Atypical features on CXR indicating impaired immune
response, including absence of cavitation, have been
associated with HIV,24 and are more common among
patients with more severe CD4 depletion.25
The LUSKAR trial was not designed to compare
differences between the two trial sites, and as only
13% of the patients in the trial were recruited in
Table 2 Demographic and clinical characteristics of 
HIV-positive patients with tuberculosis in Zambia and 
Malawi at baseline and at the end of treatment (32 weeks)
Risk factor
Lusaka
(n  676)
n (%)
Karonga
(n  84)
n (%) P value
Sex
Male 353 (52.2) 40 (47.6)
Female 323 (47.8) 44 (52.4) 0.43
Age, years
35 343 (50.7) 30 (35.7)
35–45 242 (35.8) 35 (41.7)
45 91 (13.5) 19 (22.6) 0.01
BMI, kg/m2
16 127 (18.9) 21 (25.9)
16–18.5 302 (44.9) 36 (44.4)
18.5 243 (36.2) 24 (29.6) 0.26
Haemoglobin, g/dl
8 89 (13.6) 16 (19.5)
8–10 222 (33.9) 17 (20.7)
10 343 (52.5) 49 (59.8) 0.04
HIV clinical stage*
1 543 (80.3) 58 (69.1)
2 35 (5.2) 10 (11.9)
3 78 (11.5) 11 (13.1)
4 20 (3.0) 5 (6.0) 0.03
Presence of cavity
No 218 (37.5) 38 (54.3)
Yes 363 (62.5) 32 (45.7) 0.007
Hilar/mediastinal
adenopathy
Absent 515 (88.6) 59 (84.3)
Present 66 (11.4) 11 (15.7) 0.29
Miliary TB
No 577 (99.3) 69 (98.6)
Yes 4 (0.7) 1 (1.4) 0.50
Pleural effusion
0 510 (87.8) 57 (81.4)
1/3 71 (12.2) 13 (18.6) 0.13
Infiltration
No 40 (6.9) 7 (10.0)
Yes 541 (93.2) 63 (90.0) 0.34
Area of lungs affected
1 177 (30.5) 25 (35.7)
1–2 293 (50.4) 27 (38.6)
3–6 111 (19.1) 18 (25.7) 0.16
HIV clinical staging
week 32†
1 444 (89.3) 35 (63.6)
2 7 (1.4) 7 (12.7)
3 36 (7.2) 8 (14.6)
4 10 (2.0) 5 (9.1) 0.001
* Excluding TB and signs and symptoms related to it.
† Based on symptoms at week 32. X-rays of all patients were not available.
HIV  human immunodeficiency virus; BMI  body mass index; TB 
tuberculosis.
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Karonga the power of the comparison is limited. The
mortality rates among the HIV-negative patients also
differed by site, but there were a few deaths and this
could be due to chance.
Although the same protocol was in place in both
sites, there were differences in the selection of patients:
in Karonga, 8% of screened patients were excluded
because they were too ill (unlikely to survive 2 weeks),
compared to only 0.3% in Lusaka. This may explain
the similar survival patterns during the first few months
of treatment. However, whereas all available patients
were screened in Karonga, patients were pre-screened
at peripheral clinics and then referred to the hospital
in Lusaka, so some very ill patients may have been ex-
cluded at this stage. There may also have been differ-
ences in assessing clinical signs and symptoms between
sites, although the CXRs were read blind to site. Slightly
different treatment regimens were used in the two
sites, but the efficacies of EMB and SM as part of the
standard regimen have been shown to be similar.26
The proportion of patients lost to follow-up was
small, but differed between the sites. By 12 months,
the outcome was unknown for 11.7% of patients in
Lusaka and 6% in Karonga. In a study elsewhere in Ma-
lawi, a third of all TB patients with unknown out-
come were found to have died;27 this could be higher
Table 3 Mortality rates for HIV-positive patients with tuberculosis throughout the follow-up period in Lusaka and Karonga
Risk factor
Lusaka Karonga
Deaths
n Rate (95%CI) HR
Deaths
n Rate (95%CI) HR
Sex
Female 85 17.0 (13.7–21.0) 1 18 29.6 (18.7–47.0) 1
Male 97 19.4 (15.9–23.7) 1.13 (0.8–1.5) 16 30.4 (18.6–49.6) 1.04 (0.5–2.0)
Age, years
35 64 11.7 (9.2–15.0) 1 12 30.3 (17.2–53.3) 1
35–45 75 21.8 (17.4–27.4) 1.84 (1.3–2.6) 11 20.5 (11.3–37.0) 0.69 (0.3–1.5)
45 43 38.7 (28.7–52.1) 3.13 (2.1–4.6) 11 55.0 (30.4–99.3) 1.88 (0.8–4.3)
BMI, kg/m2
16 49 29.0 (21.9–38.4) 1 11 48.6 (26.9–87.8) 1
16–18.5 74 16.4 (13.0–20.6) 0.57 (0.4–0.8) 15 27.8 (16.7–46.1) 0.60 (0.3–1.3)
18.5 57 15.2 (11.7–19.7) 0.53 (0.4–0.8) 8 24.3 (12.1–48.6) 0.51 (0.2–1.3)
Haemoglobin, g/dl
8 53 60.2 (46.0–78.8) 1 8 47.8 (23.9–95.6) 1
8–10 68 21.8 (17.2–27.6) 0.39 (0.3–0.5) 11 53.5 (29.6–96.5) 1.16 (0.5–2.9)
10 56 9.9 (7.6–12.9) 0.18 (0.1–0.3) 14 19.1 (11.3–32.3) 0.42 (0.2–1.0)
HIV stage
1 121 14.8 (12.3–17.6) 1 19 23.3 (14.8–36.6) 1
2 11 17.9 (9.9–32.4) 1.28 (0.7–2.4) 6 51.8 (23.3–115.3) 2.15 (0.8–5.4)
3 37 40.5 (29.3–55.9) 2.65 (1.8–3.8) 8 64.6 (32.3–129.2) 2.70 (1.2–6.2)
4 13 47.3 (27.5–81.5) 3.19 (1.8–5.6) 1 12.5 (1.8–89.0) 0.58 (0.1–4.3)
Presence of cavity
No 82 26.0 (20.9–32.3) 1 21 43.4 (28.3–66.6) 1
Yes 66 11.9 (9.4–15.2) 0.47 (0.4–0.6) 9 16.8 (8.4–33.6) 0.39 (0.2–0.9)
Hilar/mediastinal adenopathy
0 116 14.9 (12.4–17.9) 1 25 30.4 (20.6–45.0) 1
1 32 35.4 (25.0–50.0) 2.37 (1.6–3.5) 4 29.0 (10.9–77.2) 0.96 (0.3–2.8)
Miliary tuberculosis
No 147 17.1 (14.5–20.0) 1 28 29.8 (20.6–43.2) 1
Yes 1 13.8 (1.9–97.9) 0.84 (0.1–6.0) 1 47.5 (6.7–337.2) 1.44 (0.2–10.7)
Pleural effusion
Absent 131 16.9 (14.2–20.0) 1 22 28.5 (18.7–43.2) 1
Present 17 18.4 (11.4–29.5) 1.08 (0.6–1.8) 7 37.5 (17.9–79.7) 1.38 (0.6–3.2)
Infiltration
No 16 26.6 (16.3–43.4) 1 5 62.7 (26.1–150.6) 1
Yes 132 16.3 (13.7–19.3) 0.61 (0.4–1.0) 24 27.3 (18.3–40.7) 0.46 (0.2–1.2)
Area of lungs affected
1 66 26.3 (20.7–33.5) 1 14 43.76 (25.9–73.9) 1
1–2 59 12.6 (9.7–16.2) 0.49 (0.3–0.7) 9 25.2 (13.1–48.4) 0.57 (0.2–1.3)
3–6 23 15.4 (10.2–23.1) 0.58 (0.4–0.9) 6 21.3 (9.5–47.3) 0.48 (0.2–1.3)
HIV stage week 32*
1 55 9.9 (7.6–13) 1 5 12.4 (5.2–29.8) 1
2 3 38.1 (12.3–118.3) 3.65 (1.1–11.7) 2 23.6 (5.9–94.4) 1.94 (0.4–10.0)
3 14 45.6 (27.0–77.0) 4.53 (2.5–8.2) 4 42.8 (16.1–114.1) 3.23 (0.9–12.1)
4 4 41.7 (15.6–111.1) 4.37 (1.6–12.1) 2 63.5 (15.9–253.8) 6.31 (1.1–34.7)
* Mortality rates after the end of treatment are shown.
HIV  human immunodeficiency virus; CI  confidence interval; HR  hazard ratio; BMI  body mass index.
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among HIV-positive patients, so the mortality rate in
Lusaka may have been underestimated.
Although several risk factors were examined, there
is probably considerable residual confounding. CD4
counts, which would better measure the degree of im-
mune suppression than clinical signs and symptoms
alone, were available for only a subset of patients in
Lusaka and were not included in the analysis. Socio-
economic status was not recorded. Karonga being a
rural district, the majority of the population are sub-
sistence farmers, while Lusaka is a capital city; socio-
economic differences between patients at the two sites
are therefore likely. Information on delay of treat-
ment was not collected, and it is likely that access to
health care in Karonga was more difficult.
It is not clear why HIV-infected patients with smear-
positive TB in Karonga should have more advanced
HIV disease than similar patients in Lusaka. In both
sites, the most common type of HIV is subtype C.28,29
The HIV epidemic peaked later in Karonga than in Lu-
saka: in Lusaka, 77% of TB patients were HIV-infected
by 1989,2 whereas in Karonga the proportion increased
from 21.3% in 1989 to 38.4% in 1993 and to 70% in
1999/2000.30 This would be expected to lead to a
higher proportion of patients with HIV infections of
longer duration in Lusaka. It is possible that in Lusaka
non-tuberculosis antibiotics are more easily available
or more readily used by patients as soon as they have
signs of infection. Several studies have shown reduc-
tions in mortality among HIV-infected patients with TB
who were taking cotrimoxazole prophylaxis.7,31–34 Even
if ad-hoc treatment of established infections is not as ef-
ficient as prophylaxis, it is probably better than nothing.
As we have shown in our analysis, mortality rates
differ even between trial settings. The main prevent-
able reason for the increased mortality in Karonga
was advanced HIV disease. It is therefore of utmost
importance to maximise efforts to slow the advance of
HIV disease by making ART available and also by pro-
viding other interventions known to reduce mortality
among patients co-infected with HIV35 and M. tuber-
culosis, such as cotrimoxazole prophylaxis. This is
now beginning to happen in Malawi36 and elsewhere.
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R É S U M É
CONTEXTE : Essai clinique contrôlé randomisé d’une vac-
cination par Mycobacterium vaccae comme complément
au traitement antituberculeux chez les patients séroposi-
tifs pour le virus de l’immunodéficience humaine (VIH),
atteints d’une tuberculose (TB) à bacilloscopie positive
des crachats à Lusaka, Zambie et Karonga, Malawi.
OBJECTIF : Expliquer la différence de mortalité entre les
deux sites d’essai et identifier les facteurs de risque de
décès chez les patients séropositifs pour le VIH atteints
de TB.
SCHÉMA : On a recueilli des informations sur les carac-
téristiques démographiques, cliniques, de laboratoire et
de radiographie. On a suivi les patients à Lusaka (n 
667) et à Karonga (n  84) pendant une durée moyenne
de 1,56 années. Les analyses proportionnelles de risque
de Cox ont été utilisées pour évaluer les différences de
survie entre les deux sites et pour déterminer les facteurs
de risque en association avec la mortalité au cours du
traitement ou après traitement antituberculeux.
RÉSULTATS : Le taux de létalité des cas était de 14,7% à
Lusaka et de 21,4% à Karonga. Le ratio de risque de
décès comparant Karonga à Lusaka est de 1,47 (IC95%
0,9–2,4) au cours de traitement et de 1,76 (IC95% 1,0–
3,0) après traitement. Cette différence pourrait être
presque entièrement expliquée par un âge plus avancé
et une maladie VIH plus avancée chez les patients de
Karonga.
CONCLUSION : Il est important de comprendre les rai-
sons des différences de mortalité entre populations chez
les patients atteints de TB et d’infection par le VIH et
d’accroître au maximum les efforts de réduction de la
mortalité.
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R E S U M E N
MARCO DE REFERENCIA : Estudio clínico comparativo
aleatorizado de la vacunación con Mycobacterium vac-
cae como medida complementaria al tratamiento anti-
tuberculoso en pacientes con serología positiva para el
virus de la inmunodeficiencia humana (VIH) y tubercu-
losis (TB) con baciloscopia positiva en Lusaka, Zambia
y Karonga, en Malawi.
OBJETIVO : Explicar la diferencia de mortalidad entre
dos centros del estudio y determinar los factores de riesgo
de muerte en los pacientes con TB y serología positiva
para el VIH.
MÉTODO : Se recopiló información sobre las caracterís-
ticas demográficas, clínicas y radiográficas. Se practicó el
seguimiento de 667 pacientes en Lusaka y 84 en Karonga
durante un promedio de 1,56 años. Se aplicaron los mo-
delos de riesgos instantáneos proporcionales de Cox, con
el fin de evaluar las diferencias de supervivencia entre los
dos centros y determinar los factores de riesgo asociados
con la mortalidad durante el tratamiento antitubercu-
loso y después del mismo.
RESULTADOS : El índice de letalidad fue 14,7% en Lu-
saka y 21,4% en Karonga. Comparando Karonga con
Lusaka, el cociente de riesgos instantáneos de muerte fue
1,47 (IC95% 0,9–2,4) durante el tratamiento y 1,76
(IC95% 1,0–3,0) después del mismo. Esta diferencia se
podría explicar casi totalmente por la mayor edad y el
estado más avanzado de la enfermedad por el VIH de los
pacientes de Karonga.
CONCLUSIÓN : Es importante comprender el origen de
las diferencias entre las poblaciones con respecto a la
mortalidad de los pacientes con TB e infección por el
VIH y maximizar los esfuerzos tendientes a reducir esta
mortalidad.
